日本語AIでPubMedを検索
抗血小板治療中の患者が黄体腺腫の手術を受けた際に出血性変質を呈した脳血管事故.
[Cerebrovascular accident with haemorrhagic transformation in a patient on antiplatelet treatment subjected to surgery of a hypophyseal macroadenoma].
PMID: 22809577 DOI: 10.1016/j.redar.2012.06.003.
抄録
症例は51歳の女性で,手術日の10週間前に脳梗塞を発症した際に診断されたophyseal macroadenomaの内視鏡的内鼻経蝶形骨切除術を提案された.この間,抗血小板薬による治療を受けていたが,手術の5日前に中止された.手術は何事もなく行われた。術後2日目に左小脳半球の虚血性梗塞を発症し,水頭症の徴候と後出血性転化を認め,術後5日目に脳死を呈した.脳神経外科の周術期における抗血小板薬の使用については、確定的なガイドラインはない。また、脳血管イベントが発生してから手術までの待ち時間については合意がなく、4週間から12週間が最も望ましいとされています。手術前の各患者の個別の評価の重要性が強調されているだけでなく、脳神経外科手術の文脈で血栓症のリスクを持つ患者の抗血小板管理のレビュー、およびそれらの可能性のある術後合併症。
The case is presented of a 51 year-old woman, proposed for endoscopic endonasal transsphenoidal resection of a hypophyseal macroadenoma diagnosed in the context of a stroke suffered 10 weeks before the date of the surgery. During this time, she had been treated with antiplatelet drugs, which were withdrawn 5 days before the surgery. The surgical procedure was performed without any incidents. On the second day after the surgery, the patient had an ischaemic infarction of the left cerebellar hemisphere, with signs of hydrocephaly and a posterior haemorrhagic transformation, with brain death 5 days after the operation. There are no definitive guidelines on the use of antiplatelet drugs in the perioperative period of neurosurgery. Also, there is no agreement as regards the waiting time between a cerebrovascular event and surgery, it appears that between 4 and 12 weeks would be the most advisable. The importance of an individual assessment of each patient before surgery is emphasised, as well as a review of the antiplatelet management of the patient with a risk of thrombosis in the context of neurosurgery, and their possible postoperative complications.
Copyright © 2011 Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor. Published by Elsevier España. All rights reserved.